Advanced search
Publication Cover
Acta Oncologica Volume 48, 2009 - Issue 7
Journal homepage
11,514
Views
216
CrossRef citations to date
0
Altmetric
Review Article

Cardiotoxicity induced by tyrosine kinase inhibitors

George S. Orphanos Department of Oncology, Ygia Polyclinic, Limassol, CyprusCorrespondence[email protected]
,
George N. Ioannidis Department of Oncology, Nicosia General Hospital, Nicosia, Cyprus
&
Alexandros G. Ardavanis First Department of Medical Oncology, Saint Savvas Anticancer Hospital, Athens, Greece
Pages 964-970 | Received 03 Feb 2009, Published online: 08 Oct 2009

Citations (216)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (19)

Alicia Rosell-Hidalgo, Christopher Bruhn, Emma Shardlow, Ryan Barton, Stephanie Ryder, Timur Samatov, Alexandra Hackmann, Gerald Ryan Aquino, Micael Fernandes Dos Reis, Vladimir Galatenko, Ruediger Fritsch, Cord Dohrmann & Paul A Walker. (2023) In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes. Expert Opinion on Drug Metabolism & Toxicology 0:0, pages 1-23.
Read now
Nicola Pugliese, Ludovico Alfarone, Ivan Arcari, Silvia Giugliano, Tommaso Lorenzo Parigi, Maria Rescigno, Ana Lleo & Alessio Aghemo. (2023) Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Review of Gastroenterology & Hepatology 17:1, pages 31-43.
Read now
Liyu Jiang, Li Ping, Hao Yan, Xiaochun Yang, Qiaojun He, Zhifei Xu & Peihua Luo. (2020) Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opinion on Drug Metabolism & Toxicology 16:9, pages 823-835.
Read now
Diwakar Jain & Wilbert Aronow. (2019) Cardiotoxicity of cancer chemotherapy in clinical practice. Hospital Practice 47:1, pages 6-15.
Read now
Maher Chaar, Jeff Kamta & Sihem Ait-Oudhia. (2018) Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities. OncoTargets and Therapy 11, pages 6227-6237.
Read now
Meinolf Suttorp, Martin Bornhäuser, Markus Metzler, Frédéric Millot & Eberhard Schleyer. (2018) Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Review of Clinical Pharmacology 11:3, pages 219-231.
Read now
Gil Awada, Evandro de Azambuja & Ahmad Awada. (2017) Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. Expert Opinion on Drug Metabolism & Toxicology 13:12, pages 1205-1215.
Read now
Ivanna Hrynchak, Emília Sousa, Madalena Pinto & Vera Marisa Costa. (2017) The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metabolism Reviews 49:2, pages 158-196.
Read now
Liyun Cao, Wuqiang Zhu, Elizabeth A. Wagar & Qing H. Meng. (2017) Biomarkers for monitoring chemotherapy-induced cardiotoxicity. Critical Reviews in Clinical Laboratory Sciences 54:2, pages 87-101.
Read now
Massimo Breccia, Gioia Colafigli, Matteo Molica & Giuliana Alimena. (2016) Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Expert Opinion on Drug Safety 15:4, pages 525-533.
Read now
Giuseppe Bronte, Enrico Bronte, Giuseppina Novo, Gianfranco Pernice, Francesca Lo Vullo, Emmanuela Musso, Fabrizio Bronte, Eliana Gulotta, Sergio Rizzo, Christian Rolfo, Nicola Silvestris, Viviana Bazan, Salvatore Novo & Antonio Russo. (2015) Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety 14:2, pages 253-267.
Read now
Hyun Seok Shim & Seung Hoon Woo. (2013) Vocal fold hemorrhage in a CML patient after Glivec treatment. Acta Oncologica 52:4, pages 866-868.
Read now
Carla Minoia, Margherita Giannoccaro, Angela Iacobazzi, Daniele Santini, Nicola Silvestris, Agnese Fioretti, Stefano Oliva & Attilio Guarini. (2012) Antineoplastic drug-induced bradyarrhythmias. Expert Opinion on Drug Safety 11:5, pages 739-751.
Read now
Fable Zustovich, Giuseppe Lombardi & Patrizia Farina. (2012) Treating patients with metastatic renal carcinoma: an escape from Phase III. Expert Review of Anticancer Therapy 12:7, pages 919-927.
Read now
Constantin A Dasanu, Premkumar Padmanabhan, Bernard A. Clark$suffix/text()$suffix/text() & Christine Do. (2012) Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Expert Opinion on Drug Safety 11:3, pages 445-457.
Read now
Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Massimo Dal Bianco, Luca De Zorzi, Maurizia Dalla Palma, Ornella Nicoletto & Vittorina Zagonel. (2011) Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access Journal of Urology 3, pages 69-82.
Read now
Mila Petrova, Zhasmina Mihaylova & Albena Fakirova. (2010) Sorafenib in metastatic MTC – a case report and minireview of the literature. International Medical Case Reports Journal 3, pages 55-58.
Read now
Yolanda B. Brauchli, Thomas Wais, Alois Gratwohl, Dominik Heim, Alexander Schipf, Joachim Diebold & Stephan Krähenbühl. (2010) Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient. Acta Oncologica 49:4, pages 523-525.
Read now
Laura Cannella, Massimo Breccia, Giuseppina Loglisci, Vincenzo Federico, Michelina Santopietro & Giuliana Alimena. (2010) Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. Acta Oncologica 49:3, pages 399-400.
Read now

Articles from other publishers (197)

Alessandro Pesaresi. (2024) Nonallosteric activation of posttranslational modification enzymes by active site-directed inhibitors. Computational and Structural Biotechnology Journal 23, pages 34-42.
Crossref
Payal Kamboj, Anjali, Khalid Imtiyaz, Moshahid A. Rizvi, Virendra Nath, Vipin Kumar, Asif Husain & Mohd. Amir. (2024) Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents. Scientific Reports 14:1.
Crossref
Daria Monogiou Belik, Riccardo Bernasconi, Lifen Xu, Giacomo Della Verde, Vera Lorenz, Vivienne Grüterich, Melania Balzarolo, Michika Mochizuki, Otmar Pfister & Gabriela M. Kuster. (2023) The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice. Apoptosis 29:3-4, pages 357-371.
Crossref
Petra Kleinbongard & Ioanna Andreadou. (2024) Is There a Mitochondrial Protection via Remote Ischemic Conditioning in Settings of Anticancer Therapy Cardiotoxicity?. Current Heart Failure Reports.
Crossref
Fang Cheng, Hongxiang Wang, Weiming Li & Yu Zhang. (2024) Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective. Critical Reviews in Oncology/Hematology 195, pages 104258.
Crossref
Azin Vakilpour, Bénédicte Lefebvre, Catherine Lai & Marielle Scherrer-Crosbie. (2024) Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies. Blood Reviews 64, pages 101166.
Crossref
Chenchen Meng, Xiaoming Wang, Lu Fan, Yajie Fan, Zhipeng Yan, Yunjiao Wang, Yanyang Li, Junping Zhang & Shichao Lv. (2024) A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology. Biomedicine & Pharmacotherapy 170, pages 115588.
Crossref
Elisabeth Koch & Stephanie Plassmann. 2024. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development 9 47 .
J. Anakha, Prakashkumar Dobariya, Shyam Sunder Sharma & Abhay H. Pande. (2023) Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status. Medical Oncology 41:1.
Crossref
Antonia Chan, Stefan Torelli, Evaline Cheng, Ryan Batchelder, Sarah Waliany, Joel Neal, Ronald Witteles, Patricia Nguyen, Paul Cheng & Han Zhu. (2023) Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine 25:12, pages 715-735.
Crossref
Peng Tang, Jinjian Zhou, Huagang Liu, Shenglan Mei, Kai Wang & Hao Ming. (2023) Depletion of lncRNA MEG3 Ameliorates Imatinib-Induced Injury of Cardiomyocytes via Regulating miR-129-5p/HMGB1 Axis. Analytical Cellular Pathology 2023, pages 1-10.
Crossref
Žiga Žagar & Jarno M. Schmidt. (2023) A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions. Animals 13:19, pages 3059.
Crossref
Carmine Rocca, Teresa Soda, Ernestina Marianna De Francesco, Marco Fiorillo, Francesco Moccia, Giuseppe Viglietto, Tommaso Angelone & Nicola Amodio. (2023) Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. Journal of Translational Medicine 21:1.
Crossref
C. Altrocchi, K. Van Ammel, M. Steemans, M. Kreir, F. Tekle, A. Teisman, D. J. Gallacher & H. R. Lu. (2023) Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Frontiers in Pharmacology 14.
Crossref
Ram Kumar, Sanjay Barua, Bhupendra Nath Tripathi & Naveen Kumar. (2023) Role of ROCK signaling in virus replication. Virus Research 329, pages 199105.
Crossref
Wei-Ting Chang, Hui-Wen Lin, Ting-Chia Chang, Sheng-Hsiang Lin & Yi-Heng Li. (2023) Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan. JAMA Network Open 6:5, pages e2313824.
Crossref
Wei-Ting Chang, Hui-Wen Lin, Ting-Chia Chang, Sheng-Hsiang Lin & Yi-Heng Li. (2023) The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan. Frontiers in Oncology 13.
Crossref
Hasan Kobat, Islam Elkonaissi, Emma Foreman, Mary O’Brien, Mehmet Tevfik Dorak & Shereen Nabhani-Gebara. (2022) Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?. Journal of Oncology Pharmacy Practice 29:3, pages 646-662.
Crossref
Xiao Zhang, Yiqiang Gao, Benyu Yang, Siqing Ma, Wei Zuo & Junji Wei. (2023) The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. International Immunopharmacology 117, pages 109895.
Crossref
Toufik Abdul-Rahman, Alden Dunham, Helen Huang, Syed Muhammad Awais Bukhari, Aashna Mehta, Wireko A. Awuah, Deba Ede-Imafidon, Emiliano Cantu-Herrera, Suprateeka Talukder, Amogh Joshi, Deborah W. Sundlof & Rahul Gupta. (2023) Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. Current Problems in Cardiology 48:4, pages 101591.
Crossref
Nicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, Daniel Addison, Michael Fradley, Jorge Cortes, Neal L. Weintraub, Nazish Sayed, Girindra Raval & Avirup Guha. (2023) Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Current Cardiology Reports 25:4, pages 269-280.
Crossref
Adriatik Berisha, Angelo Placci & Pier Paolo Piccaluga. (2023) Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients. Hemato 4:1, pages 68-75.
Crossref
Gang Lv, Qiong Shi, Ting Zhang, Jinhua Li, Yan Long, Wenhui Zhang, Namrta Choudhry, Kevin Yang, Hongmei Li, Julia Kalashova, Chenglu Yang, Xiaohu Zhou, Mallu Chenna Reddy, Kishore Kumar Anantoju, Shenqiu Zhang, Jing Zhang, Thaddeus D. Allen, Hong Liu, Naganna Nimishetti & Dun Yang. (2023) Integrating a phenotypic screening with a structural simplification strategy to identify 4-phenoxy-quinoline derivatives to potently disrupt the mitotic localization of Aurora kinase B. Bioorganic & Medicinal Chemistry 80, pages 117173.
Crossref
Manar Elmadani, Sami Raatikainen, Orvokki Mattila, Tarja Alakoski, Jarkko Piuhola, Pirjo Åström, Olli Tenhunen, Johanna Magga & Risto Kerkelä. (2023) Dasatinib targets c-Src kinase in cardiotoxicity. Toxicology Reports 10, pages 521-528.
Crossref
Yap Jiajun & Hu Jiancheng. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 39 .
Mohammad Nawaf AlShatnawi, Rzan Atef Shawashreh, Mohammed Ashraf Sunoqrot & Ali Rezeq Yaghi. (2022) A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management. The Egyptian Journal of Internal Medicine 34:1.
Crossref
Kashif Haider, Shivani Sharma, Yuba Raj Pokharel, Subham Das, Alex Joseph, Abul Kalam Najmi, Faiz Ahmad & Mohammad Shahar Yar. (2022) Synthesis, biological evaluation, and in silico studies of indole‐tethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα. Drug Development Research 83:7, pages 1555-1577.
Crossref
Ainun Nizar Masbuchin, Widodo, Mohammad Saifur Rohman & Ping-Yen Liu. (2022) The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?. Frontiers in Cardiovascular Medicine 9.
Crossref
Yuko Fukuda, Yoshitaka Kawa, Akiko Nonaka & Hideyuki Shiotani. (2022) Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report. Clinical Case Reports 10:9.
Crossref
Fiorentina Guida, Riccardo Masetti, Laura Andreozzi, Daniele Zama, Marianna Fabi, Matteo Meli, Arcangelo Prete & Marcello Lanari. (2022) The Role of Nutrition in Primary and Secondary Prevention of Cardiovascular Damage in Childhood Cancer Survivors. Nutrients 14:16, pages 3279.
Crossref
Zeeshan Hussain, Lauren Baldassarre, Susan Dent, Neal L Weintraub & Avirup Guha. (2022) Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. European Journal of Preventive Cardiology 29:9, pages 1309-1311.
Crossref
Lucia Mangone, Francesco Marinelli, Luigi Tarantini, Cristina Masini, Alessandro Navazio, Stefania Di Girolamo, Isabella Bisceglia & Carmine Pinto. (2022) Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020. Biology 11:7, pages 1048.
Crossref
Cécile Conte, Flora Vayr, Marie-Christelle Pajiep, Fabien Despas, Françoise Huguet, Maryse Lapeyre Mestre, Martin Gauthier & Fabrice Herin. (2022) Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study. Supportive Care in Cancer 30:6, pages 5431-5440.
Crossref
Yudai Hojo, Shingo Kishi, Shiori Mori, Rina Fujiwara-Tani, Takamitsu Sasaki, Kiyomu Fujii, Yukiko Nishiguchi, Chie Nakashima, Yi Luo, Hisashi Shinohara & Hiroki Kuniyasu. (2022) Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8. International Journal of Molecular Sciences 23:7, pages 4002.
Crossref
Suet Nee Chen, Chi Keung Lam, Ying-Wooi Wan, Shanshan Gao, Olfat A. MalakShane Rui Zhao, Raffaella Lombardi, Amrut V. Ambardekar, Michael R. Bristow, Joseph ClevelandMarta GigliGianfranco SinagraSharon Graw, Matthew R.G. Taylor, Joseph C. Wu & Luisa Mestroni. (2022) Activation of PDGFRA signaling contributes to filamin C–related arrhythmogenic cardiomyopathy. Science Advances 8:8.
Crossref
Jamal Bouitbir, Miljenko V. Panajatovic & Stephan Krähenbühl. (2022) Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line. International Journal of Molecular Sciences 23:4, pages 2282.
Crossref
Kihyoun Park & Myung-Shik Lee. (2022) Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases. Frontiers in Cell and Developmental Biology 10.
Crossref
Asif Husain, Silky Bedi, Shazia Parveen, Shah Alam Khan, Aftab Ahmad, Md Azhar Iqbal, Aasif Farooq & Anwar Ahmed. (2022) Furanone-functionalized benzothiazole derivatives: synthesis, in vitro cytotoxicity, ADME, and molecular docking studies . Zeitschrift für Naturforschung B 77:1, pages 41-53.
Crossref
Khawar Ali, Wenjuan Li, Yaopeng Qin, Shanshan Wang, Lijie Feng, Qiang Wei, Qunwei Bai, Bowen Zheng, Guishuang Li, Hongyan Ren & Guang Wu. (2022) Kinase Function of Brassinosteroid Receptor Specified by Two Allosterically Regulated Subdomains. Frontiers in Plant Science 12.
Crossref
PSanjay Chakravarthy, Pushpa Kumari, DipendraKumar Gupta, Mithu Bhowmick, MDevendra Naik & Gudimetla Priyanka. (2022) Imatinib-induced cardiotoxicity: A study to evaluate cardiac functions in patients on imatinib therapy for chronic myeloid leukemia. Journal of Applied Hematology 13:2, pages 71.
Crossref
Neeraj Chhabra & Joseph Kennedy. (2021) A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. Journal of Medical Toxicology 18:1, pages 43-55.
Crossref
Shane S. Scott, Ashley N. Greenlee, Ethan J. Schwendeman, Somayya J. Mohammad, Michael T. Naughton, Anna Matzko, Mamadou Diallo, Matthew Stein, Rohith Revan, Taborah Z. Zaramo, Gabriel Shimmin, Shwetabh Tarun, Joel Ferrall, Thai H. Ho & Sakima A. Smith. 2022. Cardiovascular Signaling in Health and Disease. Cardiovascular Signaling in Health and Disease 111 173 .
Ling-Jun Jie, Yun-Da Li, He-Qiang Zhang, Liang Mao, Hua-Bin Xie, Fa-Guang Zhou, Tian-Li Zhou, Dong Xie, Jia-Le Lin, Gui-Yang Li, Bin-Ni Cai, Yan-Hui Zhang & Yan Wang. (2021) Mechanisms of gefitinib-induced QT prolongation. European Journal of Pharmacology 910, pages 174441.
Crossref
Mo-Fan Huang, Lon Kai Pang, Yi-Hung Chen, Ruiying Zhao & Dung-Fang Lee. (2021) Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cells 10:11, pages 2823.
Crossref
Katsu Ishida, Jonathan A. Werner, Rhian Davies, Fan Fan, Barbara Thomas, Jan Wahlstrom, James Russell Lipford & Thomas Monticello. (2021) Nonclinical Safety Profile of Sotorasib, a KRAS G12C -Specific Covalent Inhibitor for the Treatment of KRAS p.G12C -Mutated Cancer . International Journal of Toxicology 40:5, pages 427-441.
Crossref
Seong Bok Jang, Kyeong Bae Kim, Sujin Sim, Byoung Chul Cho, Myung-Ju Ahn, Ji-Youn Han, Sang-We Kim, Ki Hyeong Lee, Eun Kyung Cho, Nahor Haddish-Berhane, Jaydeep Mehta & Se-Woong Oh. (2021) Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports 2:10, pages 100224.
Crossref
Yogesh Chander, Ram Kumar, Nitin Khandelwal, Namita Singh, Brij Nandan Shringi, Sanjay Barua & Naveen Kumar. (2021) Role of p38 mitogen‐activated protein kinase signalling in virus replication and potential for developing broad spectrum antiviral drugs. Reviews in Medical Virology 31:5, pages 1-16.
Crossref
Chengyi Tu, Nathan J. Cunningham, Mao Zhang & Joseph C. Wu. (2021) Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity. Frontiers in Pharmacology 12.
Crossref
Manvendra Kumar, Gaurav Joshi, Sahil Arora, Tashvinder Singh, Sajal Biswas, Nisha Sharma, Zahid Rafiq Bhat, Kulbhushan Tikoo, Sandeep Singh & Raj Kumar. (2021) Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment. Molecules 26:5, pages 1490.
Crossref
Ugur Nadir Karakulak, Elifcan Aladag, Vedat Hekimsoy, Mehmet Levent Sahiner, Ergun Baris Kaya, Necla Ozer, Salih Aksu, Haluk Demiroglu, Hakan Goker, Yahya Buyukasik, Osman Ozcebe, Nilgun Sayinalp & Ibrahim Celalettin Haznedaroglu. (2020) Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors. Cardiovascular Toxicology 21:3, pages 216-223.
Crossref
Hasan Kobat, Islam Elkonaissi, Mehmet Tevfik Dorak & Shereen Nabhani-Gebara. (2021) Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. Oncology Reviews 15:1.
Crossref
Anca Bojan, Tunde Torok-Vistai & Andrada Parvu. (2021) Assessment and Management of Cardiotoxicity in Hematologic Malignancies. Disease Markers 2021, pages 1-10.
Crossref
ShaqulQamar Wani, Khan Talib, IshtiyaqAhmad Dar, MohammadMaqbool Lone & Fir Afroz. (2021) Caution “When Rabbit Runs Turtles' Pace”: 5-fluorouracil-induced slowdown of the heart – The bradyarrhythmias. Journal of Cancer Research and Practice 8:3, pages 104.
Crossref
Astrid Weiss, Mario Boehm, Bakytbek Egemnazarov, Friedrich Grimminger, Soni Savai Pullamsetti, Grazyna Kwapiszewska & Ralph T. Schermuly. (2020) Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. British Journal of Pharmacology 178:1, pages 31-53.
Crossref
Logan Dunkenberger & Ioannis Karakikes. 2021. Recent Advances in iPSC Technology. Recent Advances in iPSC Technology 1 22 .
Valentina Giudice, Carmine Vecchione & Carmine Selleri. (2020) Cardiotoxicity of Novel Targeted Hematological Therapies. Life 10:12, pages 344.
Crossref
Xinhua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, Lujian Liao, Bo Jiao & Ruibao Ren. (2020) Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. Journal of Hematology & Oncology 13:1.
Crossref
Epameinondas Koumpis, Matilda Florentin, Eleftheria Hatzimichael & George Liamis. (2020) Hyponatremia in Patients with Hematologic Diseases. Journal of Clinical Medicine 9:11, pages 3721.
Crossref
Paz Ovics, Danielle Regev, Polina Baskin, Mor Davidor, Yuval Shemer, Shunit Neeman, Yael Ben-Haim & Ofer Binah. (2020) Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening. International Journal of Molecular Sciences 21:19, pages 7320.
Crossref
Md Azhar Iqbal, Asif Husain, Ozair Alam, Shah A. Khan, Aftab Ahmad, Md Rafi Haider & Md Aftab Alam. (2020) Design, synthesis, and biological evaluation of imidazopyridine‐linked thiazolidinone as potential anticancer agents. Archiv der Pharmazie 353:10.
Crossref
J. G. Coen van Hasselt, Rayees Rahman, Jens Hansen, Alan Stern, Jaehee V. Shim, Yuguang Xiong, Amanda Pickard, Gomathi Jayaraman, Bin Hu, Milind Mahajan, James M. Gallo, Joseph Goldfarb, Eric A. Sobie, Marc R. Birtwistle, Avner Schlessinger, Evren U. Azeloglu & Ravi Iyengar. (2020) Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity. Nature Communications 11:1.
Crossref
Matthias Goßmann, Peter Linder, Ulrich Thomas, Krisztina Juhasz, Marta Lemme, Michael George, Niels Fertig, Elena Dragicevic & Sonja Stoelzle-Feix. (2020) Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment. Journal of Pharmacological and Toxicological Methods 105, pages 106892.
Crossref
Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Musaad A. AlShammari, Naif O. Al-Harbi, Ali Alhoshani, Homood M. As Sobeai, Mohammed AlSwayyed, Mohammed M. AlAnazi & Nader S. AlGhamdi. (2020) Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways. Saudi Pharmaceutical Journal 28:4, pages 509-518.
Crossref
Farah Nawaz, Ozair Alam, Ahmad Perwez, Moshahid A. Rizvi, Mohd. J. Naim, Nadeem Siddiqui, Faheem H. Pottoo & Mukund Jha. (2020) 3′‐(4‐(Benzyloxy)phenyl)‐1′‐phenyl‐5‐(heteroaryl/aryl)‐3,4‐dihydro‐1′ H ,2 H ‐[3,4′‐bipyrazole]‐2‐carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies . Archiv der Pharmazie 353:4, pages 1900262.
Crossref
Dae Hyun Lim, Jai Hoon Yoon, Dae Won Jun, Oh Young Lee, Byung Chul Yoon, Hang Rak Lee, Kyung Soo Kim & Ho Soon Choi. (2020) Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review. Journal of Liver Cancer 20:1, pages 67-71.
Crossref
M. E. Cabanillas & S. Takahashi. (2020) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Head and Neck Tumors (HNT) 9:4, pages 49-61.
Crossref
Sarah D. Lamore, Rebecca A. Kohnken, Matthew F. Peters & Kyle L. Kolaja. (2019) Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chemical Research in Toxicology 33:1, pages 125-136.
Crossref
Susanne Saussele, Wilhelm Haverkamp, Fabian Lang, Steffen Koschmieder, Alexander Kiani, Kathleen Jentsch-Ullrich, Frank Stegelmann, Heike Pfeifer, Paul La Rosée, Nicola Goekbuget, Christina Rieger, Cornelius F. Waller, Georg-Nikolaus Franke, Philipp le Coutre, Rudolf Kirchmair & Christian Junghanss. (2020) Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematologica 143:3, pages 217-231.
Crossref
Athina Moschopoulou, Stefan Zwirner, Lars Zender & Daniel Dauch. 2021. Proteinkinase Inhibitors. Proteinkinase Inhibitors 125 153 .
Ji Min Han & Hye Sun Gwak. (2019) Reviews on the Hepatotoxicity of Tyrosine Kinase Inhibitors. Korean Journal of Clinical Pharmacy 29:4, pages 223-230.
Crossref
Arshad J. Ansari, Gaurav Joshi, Umesh Prasad Yadav, Antim K. Maurya, Vijai K. Agnihotri, Sourav Kalra, Raj Kumar, Sandeep Singh & Devesh M. Sawant. (2019) Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors. Bioorganic Chemistry 93, pages 103314.
Crossref
Jamal Bouitbir, Abdallah Alshaikhali, Miljenko V. Panajatovic, Vanessa F. Abegg, Franziska Paech & Stephan Krähenbühl. (2019) Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib. Toxicology 426, pages 152281.
Crossref
Huan Ren. 2019. Tyrosine Kinases as Druggable Targets in Cancer. Tyrosine Kinases as Druggable Targets in Cancer.
Kazuho Sakamoto, Kohei Sakatoku, Shintaro Sugimoto, Nanami Iwasaki, Yusuke Sano, Masahiko Yamaguchi & Junko Kurokawa. (2019) Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects. Journal of Pharmacological Sciences 140:4, pages 345-349.
Crossref
Daryl Sudasena, Dinu Valentin Balanescu, Teodora Donisan, Saamir Hassan, Nicolas Palaskas, Peter Kim, Kaveh Karimzad, Juan Lopez-Mattei, Salman Arain, K. Lance Gould & Cezar Iliescu. (2018) Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovascular Toxicology 19:4, pages 382-387.
Crossref
Huan Wang, Robert P. Sheehan, Adam C. Palmer, Robert A. Everley, Sarah A. Boswell, Noga Ron-Harel, Alison E. Ringel, Kristina M. Holton, Connor A. Jacobson, Alison R. Erickson, Laura Maliszewski, Marcia C. Haigis & Peter K. Sorger. (2019) Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell Systems 8:5, pages 412-426.e7.
Crossref
Jasmin D. Haslbauer, Sarah Lindner, Gesine Bug, Eike Nagel & Valentina O. Puntmann. (2019) Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction. Current Cardiovascular Imaging Reports 12:5.
Crossref
Preetesh Jain, Hagop KantarjianPrajwal C. BodduGraciela M. Nogueras-González, Srdan VerstovsekGuillermo Garcia-ManeroGautam BorthakurKoji SasakiTapan M. KadiaPrincy SamHycienth AhanekuSusan O’Brien, Zeev EstrovFarhad RavandiElias JabbourJorge E. Cortes. (2019) Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advances 3:6, pages 851-861.
Crossref
Maria E. Cabanillas & Shunji Takahashi. (2019) Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Seminars in Oncology 46:1, pages 57-64.
Crossref
Kerstin Hiesinger, Karen M. Wagner, Bruce D. Hammock, Ewgenij Proschak & Sung Hee Hwang. (2019) Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity. Prostaglandins & Other Lipid Mediators 140, pages 31-39.
Crossref
Robert RoskoskiJr.Jr.. (2019) Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research 139, pages 395-411.
Crossref
Khushwant S. Bhullar, Naiara Orrego Lagarón, Eileen M. McGowan, Indu Parmar, Amitabh Jha, Basil P. Hubbard & H. P. Vasantha Rupasinghe. (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer 17:1.
Crossref
Kim A. Henderson, R. Brandon Borders, John B. Ross, Amir Abdulalil, Seth Gibbs, Anthony J. Skowronek, Katherine Knostman, Jay Bailey, Jeremy Smith, Tom Vinci, Brandon Wood, Michael V. Knopp & Brian M. Roche. (2018) Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations. Journal of Pharmacological and Toxicological Methods 94, pages 54-63.
Crossref
Md. Jawaid Akhtar, Ahsan Ahmed Khan, Zulphikar Ali, Rikeshwer Prasad Dewangan, Md. Rafi, Md. Quamrul Hassan, Md. Sayeed Akhtar, Anees Ahmad Siddiqui, Sangh Partap, Santosh Pasha & M. Shahar Yar. (2018) Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorganic Chemistry 78, pages 158-169.
Crossref
Traian Constantin Panciu, Bianca Masgras, Catrinel Ciuca, Raluca Ciomag, Anca Mihăilescu & Adriana Gurghean. (2018) Acute Coronary Syndrome Following Long-Term Erlotinib Treatment. Internal Medicine 15:3, pages 61-66.
Crossref
Hani M Babiker, Ali McBride, Michael Newton, Leigh M. Boehmer, Adrienne Goeller Drucker, Mollie Gowan, Manouchkathe Cassagnol, Todd D. Camenisch, Faiz Anwer & James M. Hollands. (2018) Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Critical Reviews in Oncology/Hematology 126, pages 186-200.
Crossref
Baichun Yang & Thomas Papoian. (2018) Preclinical approaches to assess potential kinase inhibitor‐induced cardiac toxicity: Past, present and future. Journal of Applied Toxicology 38:6, pages 790-800.
Crossref
Josephine T. Tauer, Bernadette A. S. Jäger, Anna Ulmer, Paula Geidel, Vera Girke, Lysann Kroschwald & Meinolf Suttorp. 2018. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy. Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy.
Hyang-Ae Lee, Sung-Ae Hyun, Byungjin Byun, Jong-Hak Chae & Ki-Suk Kim. (2018) Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes. PLOS ONE 13:4, pages e0195577.
Crossref
Devawati Dutta, Ranjita Das, Chhabinath Mandal & Chitra Mandal. (2017) Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. Journal of Chemical Information and Modeling 58:1, pages 68-89.
Crossref
I.L. Davydkin, Kseniya Viktorovna Naumova, A.M. Osadchuk, I.A. Zolotovskaya, O.E. Danilova, T.Yu. Stepanova, O.V. Tereshina, L.V. Limareva, A.S. Shpigel' & T.P. Kuz'mina. (2018) Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. Clinical oncohematology 11:4, pages 378-387.
Crossref
Leah J. Wilson, Adam Linley, Dean E. Hammond, Fiona E. Hood, Judy M. Coulson, David J. MacEwan, Sarah J. Ross, Joseph R. Slupsky, Paul D. Smith, Patrick A. Eyers & Ian A. Prior. (2018) New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Cancer Research 78:1, pages 15-29.
Crossref
Marjan Boerma. 2018. Gender Differences in the Pathogenesis and Management of Heart Disease. Gender Differences in the Pathogenesis and Management of Heart Disease 303 316 .
Catrin Hasselgren & Glenn J. Myatt. 2018. Computational Toxicology. Computational Toxicology 233 244 .
Ping‐Pin Zheng, Jin Li & Johan M Kros. (2017) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti & Mitali Dandekar. (2017) Targeted Therapy for Medullary Thyroid Cancer: A Review. Frontiers in Oncology 7.
Crossref
Genevieve Conant, Samad Ahadian, Yimu Zhao & Milica Radisic. (2017) Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires. Scientific Reports 7:1.
Crossref
Sarah D. Lamore, Ernst Ahlberg, Scott Boyer, Michelle L. Lamb, Maria P. Hortigon-Vinagre, Victor Rodriguez, Godfrey L. Smith, Johanna Sagemark, Lars Carlsson, Stephanie M. Bates, Allison L. Choy, Jonna Stålring, Clay W. Scott & Matthew F. Peters. (2017) Deconvoluting Kinase Inhibitor Induced Cardiotoxicity. Toxicological Sciences 158:1, pages 213-226.
Crossref
Genevieve Conant, Benjamin Fook Lun Lai, Rick Xing Ze Lu, Anastasia Korolj, Erika Yan Wang & Milica Radisic. (2017) High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. Stem Cell Reviews and Reports 13:3, pages 335-346.
Crossref
Wan ZhuFanxia ShenLei MaoLei ZhanShuai KangZhengda SunJeffrey NelsonRui ZhangDingquan ZouCameron M. McDougallMichael T. LawtonThiennu H. VuZhijian WuAbraham ScariaPeter ColosiJohn ForsayethHua Su. (2017) Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity. Stroke 48:5, pages 1420-1423.
Crossref
Ying Liu, Donna M. Conlon, Xin Bi, Katherine J. Slovik, Jianting Shi, Hailey I. Edelstein, John S. Millar, Ali Javaheri, Marina Cuchel, Evanthia E. Pashos, Jahangir Iqbal, M. Mahmood Hussain, Robert A. Hegele, Wenli Yang, Stephen A. Duncan, Daniel J. Rader & Edward E. Morrisey. (2017) Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports 19:7, pages 1456-1466.
Crossref
Ivo Darko Gabrić. (2017) Cardiotoxicity due to biological cancer therapy. Cardiologia Croatica 12:1-2, pages 16-22.
Crossref
Md Jawaid Akhtar, Anees Ahmad Siddiqui, Ahsan Ahmed Khan, Zulphikar Ali, Rikeshwer Prasad Dewangan, Santosh Pasha & M. Shahar Yar. (2017) Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors. European Journal of Medicinal Chemistry 126, pages 853-869.
Crossref
Varun Ahuja, Sanjay Bokan & Sharad Sharma. (2017) Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds. Drug Discovery Today 22:1, pages 127-132.
Crossref
E. Koch & S. Plassmann. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development 7 38 .
A. Lajoie, J. Dunhill & M.A. Hamilton. 2017. Cardio-Oncology. Cardio-Oncology 297 307 .
Barbara Bassani, Antonino Bruno, Nicoletta Macrì, Paola Corradino, Douglas M. Noonan & Adriana Albini. 2017. Manual of Cardio-oncology. Manual of Cardio-oncology 107 122 .
Liz Roquemore, M. Ariel Kauss, Catherine Hather, Nick Thomas & Hirdesh Uppal. 2017. Stem Cell-Derived Models in Toxicology. Stem Cell-Derived Models in Toxicology 247 269 .
D. LEKES, I. SZADVARI, O. KRIZANOVA, K. LOPUSNA, I. REZUCHOVA, M. NOVAKOVA, Z. NOVAKOVA, T. PARAK & P. BABULA. (2016) Nilotinib Induces ER Stress and Cell Death in H9c2 Cells. Physiological Research, pages S505-S514.
Crossref
Tarek Magdy, Brian T. Burmeister & Paul W. Burridge. (2016) Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. Pharmacology & Therapeutics 168, pages 113-125.
Crossref
Karima Ait-Aissa, Johnathan D. Ebben, Andrew O. Kadlec & Andreas M. Beyer. (2016) Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease. Pharmacological Research 111, pages 422-433.
Crossref
Yi Yang & Peili Bu. (2016) Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies. Chemico-Biological Interactions 257, pages 125-131.
Crossref
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann & R E Clark. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8, pages 1648-1671.
Crossref
SHANSHAN DING, FEI LONG & SHUJUAN JIANG. (2016) Acute myocardial infarction following erlotinib treatment for NSCLC: A case report. Oncology Letters 11:6, pages 4240-4244.
Crossref
Lauren Caldemeyer, Michael Dugan, John Edwards & Luke Akard. (2016) Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 11:2, pages 71-79.
Crossref
Camilo A. Velásquez, Miguel González, Marie C. Berrouet & Nicolás Jaramillo. (2016) Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Revista Colombiana de Cardiología 23:2, pages 104-111.
Crossref
Shabneez Hussain & Mohammad Usman Shaikh. (2015) Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country. Clinical Therapeutics 37:11, pages 2449-2457.
Crossref
Rob Wallis, Mayel Gharanei & Helen Maddock. (2015) Predictivity of in vitro non-clinical cardiac contractility assays for inotropic effects in humans — A literature search. Journal of Pharmacological and Toxicological Methods 75, pages 62-69.
Crossref
Matthew Trendowski. (2015) PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacological Research 99, pages 202-216.
Crossref
Liang Kong, Yue Wang, Xiao-Jing Wang, Xiao-Tong Wang, Yan Zhao, Li-Mei Wang & Zhe-Yu Chen. (2015) Retinoic acid ameliorates blood–brain barrier disruption following ischemic stroke in rats. Pharmacological Research 99, pages 125-136.
Crossref
Kimberly R. Doherty, Dominique R. Talbert, Patricia B. Trusk, Diarmuid M. Moran, Scott A. Shell & Sarah Bacus. (2015) Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicology and Applied Pharmacology 285:1, pages 51-60.
Crossref
Mark C. Munson. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety 329 364 .
Miko Kawabata, Noriko Umemoto, Yasuhito Shimada, Yuhei Nishimura, Beibei Zhang, Junya Kuroyanagi, Masayuki Miyabe & Toshio Tanaka. (2015) Downregulation of Stanniocalcin 1 Is Responsible for Sorafenib-Induced Cardiotoxicity. Toxicological Sciences 143:2, pages 374-384.
Crossref
Carine E. HamoMichelle Weisfelner Bloom. (2015) Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy. Clinical Medicine Insights: Cardiology 9s2, pages CMC.S19704.
Crossref
Christian Kollmannsberger, G. A. Bjarnason & Alain Ravaud. 2015. Kidney Cancer. Kidney Cancer 365 384 .
Luis León, Luis Miguel Antón-Aparicio, Emilio Esteban-González, Martin Lázaro-Quintela & Sergio Vázquez-Éstevez. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma 377 416 .
Arezoo Daryadel, Anna Bogdanova, Max Gassmann, Xavier Mueller, Gregor Zünd, Burkhardt Seifert, Christine Lehalle, Nelly Frossard & Reza Tavakoli. (2014) Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway. Journal of Cardiothoracic Surgery 9:1.
Crossref
Daniela Sicoli, Xuanmao Jiao, Xiaoming Ju, Marco Velasco-Velazquez, Adam Ertel, Sankar Addya, Zhiping Li, Sebastiano Andò, Alessandro Fatatis, Bishnuhari Paudyal, Massimo Cristofanilli, Mathew L. Thakur, Michael P. Lisanti & Richard G. Pestell. (2014) CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines. Cancer Research 74:23, pages 7103-7114.
Crossref
L. Mortara, G. Pera, E. Monti, S. Morbelli, F. Minuto, G. Sambuceti & M. Giusti. (2014) Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. Journal of Endocrinological Investigation 37:11, pages 1099-1108.
Crossref
Cristina Tintori, Annalaura Brai, Anna Lucia Fallacara, Roberta Fazi, Silvia Schenone & Maurizio Botta. (2014) Protein–protein interactions and human cellular cofactors as new targets for HIV therapy. Current Opinion in Pharmacology 18, pages 1-8.
Crossref
Judy Truong, Andrew T. Yan, Gemma Cramarossa & Kelvin K.W. Chan. (2014) Chemotherapy-Induced Cardiotoxicity: Detection, Prevention, and Management. Canadian Journal of Cardiology 30:8, pages 869-878.
Crossref
Jennifer A. Talarico, Rhonda L. Carter, Laurel A. Grisanti, Justine E. Yu, Ashley A. Repas & Douglas G. Tilley. (2014) β-Adrenergic Receptor-Dependent Alterations in Murine Cardiac Transcript Expression Are Differentially Regulated by Gefitinib In Vivo. PLoS ONE 9:6, pages e99195.
Crossref
Shirley A. Aguirre & Eileen R. Blasi. 2014. Predictive ADMET. Predictive ADMET 555 568 .
Hardip SandhuHelen Maddock. (2013) Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science 126:6, pages 377-400.
Crossref
Bum Soon Choi. (2014) Risks associated with sunitinib use and monitoring to improve patient outcomes. The Korean Journal of Internal Medicine 29:1, pages 23.
Crossref
Kerry Strong Russell. 2014. Evidence-Based Cardiology Consult. Evidence-Based Cardiology Consult 399 407 .
Nader Makki, Kristina Thiel & Francis MillerJr.Jr.. (2013) The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease. International Journal of Molecular Sciences 14:10, pages 20597-20613.
Crossref
Rossana Berardi, Miriam Caramanti, Agnese Savini, Silvia Chiorrini, Chiara Pierantoni, Azzurra Onofri, Zelmira Ballatore, Mariagrazia De Lisa, Paola Mazzanti & Stefano Cascinu. (2013) State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Critical Reviews in Oncology/Hematology 88:1, pages 75-86.
Crossref
Nicola Sgherza, Antonella Vita Russo Rossi, Paolo Colonna, Paola Carluccio, Mario Delia & Giorgina Specchia. (2013) Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia. International Journal of Hematology 98:4, pages 483-486.
Crossref
Hervé Spechbach, Philippe Morel, Kuntheavy Ing Lorenzini, Marie Besson, Laurent Gétaz, Henri Sunthorn & Yves Chalandon. (2013) Reversible ventricular arrythmia induced by dasatinib. Clinical Case Reports 1:1, pages 20-25.
Crossref
Kimberly A. Henderson, R. Brandon Borders, John B. Ross, Theresa B. Huwar, Calvin O. Travis, Brandon J. Wood, Zhenxu J. Ma, S. Peter Hong, Thomas M. Vinci & Brian M. Roche. (2013) Effects of tyrosine kinase inhibitors on rat isolated heart function and protein biomarkers indicative of toxicity. Journal of Pharmacological and Toxicological Methods 68:1, pages 150-159.
Crossref
T D Kim, D Rea, M Schwarz, P Grille, F E Nicolini, G Rosti, L Levato, F J Giles, H Dombret, T Mirault, H Labussière, R Lindhorst, W Haverkamp, I Buschmann, B Dörken & P D le Coutre. (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:6, pages 1316-1321.
Crossref
Kunihiro Tsuji, Kenichi Takemura, Keisuke Minami, Ryota Teramoto, Keisuke Nakashima, Shinya Yamada, Hisashi Doyama, Hisanori Oiwake & Kenkou Hasatani. (2013) A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology 6:3, pages 255-257.
Crossref
Saurabh Aggarwal, Jasmine Kamboj & Rohit Arora. (2013) Chemotherapy-related cardiotoxicity. Therapeutic Advances in Cardiovascular Disease 7:2, pages 87-98.
Crossref
Harue Sasai, Kenichi Sakakura, Koichi Yuri, Hiroshi Wada, Kenshiro Arao, Hiroshi Funayama, Yoshitaka Sugawara, Atsushi Yamaguchi, Hideo Adachi, Shin-ichi Momomura & Junya Ako. (2012) Fractional flow reserve for a mild stenosis on the donor artery to chronic total occlusion. Cardiovascular Intervention and Therapeutics 28:2, pages 193-196.
Crossref
Barbara SchreierSindy RabeBettina SchneiderMaria BretschneiderSebastian RuppStefanie RuhsJoachim NeumannUwe RueckschlossMaria SibiliaMichael GotthardtClaudia GrossmannMichael Gekle. (2013) Loss of Epidermal Growth Factor Receptor in Vascular Smooth Muscle Cells and Cardiomyocytes Causes Arterial Hypotension and Cardiac Hypertrophy. Hypertension 61:2, pages 333-340.
Crossref
Philip S. Hall, Lauren C. Harshman, Sandy Srinivas & Ronald M. Witteles. (2013) The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC: Heart Failure 1:1, pages 72-78.
Crossref
Shenjun Zhu, Sharon M Cawley, Kenneth D Bloch & Paul L Huang. (2013) Trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes. Cardiovascular System 1:1, pages 10.
Crossref
Carole Yolande PerrotDelphine JavelaudAlain Mauviel. (2013) Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Annals of Dermatology 25:2, pages 135.
Crossref
Qian Dong, Xiao-xing Fu, Li-li Du, Ning Zhao, Cheng-kun Xia, Kun-wu Yu, Long-xian Cheng & Yi-mei Du. (2013) Blocking of the Human Ether-à-go-go-Related Gene Channel by Imatinib Mesylate. Biological and Pharmaceutical Bulletin 36:2, pages 268-275.
Crossref
Marion Castel, Fabien Despas, Anouchka Modesto, Céline Gales, Benjamin Honton, Michel Galinier, Jean-Michel Senard & Atul Pathak. (2013) Effets indésirables cardiaques des chimiothérapies. La Presse Médicale 42:1, pages 26-39.
Crossref
F. Bianchi, E. Caffarri, S. Cavalli, C. Lagrasta, M. Musci, F. Quaini & M. Savi. (2013) Development and validation of an high performance liquid chromatography–tandem mass spectrometry method for the determination of imatinib in rat tissues. Journal of Pharmaceutical and Biomedical Analysis 73, pages 103-107.
Crossref
. 2013. Complications et Séquelles des Traitements en Cancérologie ORL. Complications et Séquelles des Traitements en Cancérologie ORL 125 147 .
Delphine Javelaud & Alain Mauviel. 2013. TGF-β in Human Disease. TGF-β in Human Disease 235 254 .
Giuseppe Procopio, Elena Verzoni, Isabella Testa, Nicola Nicolai, Roberto Salvioni & Filippo DeBraud. (2012) Experience with sorafenib in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology 4:6, pages 303-313.
Crossref
Eduardo Gehling Bertoldi, Milena S. Marcolino, Luis Eduardo P. Rohde, Antonio Luiz Ribeiro & Carisi A. Polanczyk. (2012) Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil. Value in Health Regional Issues 1:2, pages 180-183.
Crossref
Baichun Yang & Thomas Papoian. (2012) Tyrosine kinase inhibitor (TKI)‐induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. Journal of Applied Toxicology 32:12, pages 945-951.
Crossref
Mathieu Porceddu, Nelly Buron, Célestin Roussel, Gilles Labbe, Bernard Fromenty & Annie Borgne-Sanchez. (2012) Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria. Toxicological Sciences 129:2, pages 332-345.
Crossref
Manuela Schmidinger & Jutta Bergler‐Klein. (2012) Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. International Journal of Urology 19:9, pages 796-804.
Crossref
Rodolfo Sacco, Irene Bargellini, Barbara Ginanni, Marco Bertini, Elena Bozzi, Emanuele Altomare, Valentina Battaglia, Antonio Romano, Emanuele Tumino, Matteo Di Biase, Giampaolo Bresci & Carlo Bartolozzi. (2011) Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient. Journal of Gastrointestinal Cancer 43:S1, pages 89-92.
Crossref
Marek Svoboda, Alexandr Poprach, Svatopluk Dobes, Igor Kiss & Rostislav Vyzula. (2012) Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review. Cardiovascular Toxicology 12:3, pages 191-207.
Crossref
Aiping ZHOU. (2012) Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience. Asia-Pacific Journal of Clinical Oncology 8:2, pages 132-144.
Crossref
Martin Hohenegger. (2012) Drug induced rhabdomyolysis. Current Opinion in Pharmacology 12:3, pages 335-339.
Crossref
Zsolt Sarszegi, Eszter Bognar, Balazs Gaszner, Attila Kónyi, Ferenc GallyasJr.Jr., Balazs Sumegi & Zoltan Berente. (2012) BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Molecular and Cellular Biochemistry 365:1-2, pages 129-137.
Crossref
Tao Chen, Peter A. Stephens, Fiona K. Middleton & Nicola J. Curtin. (2012) Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 17:5-6, pages 194-202.
Crossref
Foroogh Nejatollahi, Mahdi Asgharpour & Mansooreh Jaberipour. (2011) Down-regulation of vascular endothelial growth factor expression by anti-her2/neu single chain antibodies. Medical Oncology 29:1, pages 378-383.
Crossref
Ingrid M.E. Desar, Annemarie M.J. Thijs, Sasja F. Mulder, Cees J.J. Tack, Carla M.L. van Herpen & Winette T.A. van der Graaf. (2012) Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. Anti-Cancer Drugs 23:2, pages 149-154.
Crossref
Julien EdelineElodie VauléonNathalie Rioux-LeclercqChristophe PerrinCécile Vigneau Karim BensalahBrigitte Laguerre. (2012) Safety and Efficacy of Sorafenib in Renal Cell Carcinoma. Cancer Growth and Metastasis 5, pages CGM.S7526.
Crossref
Christian Kollmannsberger, G. A. Bjarnason & Alain Ravaud. 2012. Kidney Cancer. Kidney Cancer 265 283 .
J.D. Cohen, J.E. Babiarz, R.M. Abrams, L. Guo, S. Kameoka, E. Chiao, J. Taunton & K.L. Kolaja. (2011) Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicology and Applied Pharmacology 257:1, pages 74-83.
Crossref
Lynnette HowingtonKristina RiddlespergerDennis J. Cheek. (2011) Essential Nursing Competencies for Genetics and Genomics: Implications for Critical Care. Critical Care Nurse 31:5, pages e1-e7.
Crossref
Milena S. Marcolino, Eric Boersma, Nelma C.D. Clementino, Maria do Carmo P. Nunes, Márcia M. Barbosa, Maria Helena C.R. Silva, Marcel L. Geleijnse & Antonio L. Ribeiro. (2010) The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients. Hematological Oncology 29:3, pages 124-130.
Crossref
Moira Davenport & Mary Ann Howland. 2011. Challenging and Emerging Conditions in Emergency Medicine. Challenging and Emerging Conditions in Emergency Medicine 158 183 .
Antonio Pezzano. (2011) Importance of cancer therapies induced cardiotoxicity study. Journal of Cardiovascular Echography 21:2, pages 43-44.
Crossref
Sara Di Bella, Filippo Venturini, Giovanna Marrapese, Emiliana Tarenzi & Salvatore Siena. (2011) Cardiotoxicity of novel molecular targeted therapies of cancer. Journal of Cardiovascular Echography 21:2, pages 78-85.
Crossref
T. Naib, R.M. Steingart & C.L. Chen. (2011) Sorafenib-associated multivessel coronary artery vasospasmSorafenibassozierter Spasmus mehrer Koronararterien. Herz 36:4, pages 348-351.
Crossref
Houjian CaiDaniel A. SmithSanaz Memarzadeh, Clifford A. Lowell, Jonathan A. Cooper & Owen N. Witte. (2011) Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proceedings of the National Academy of Sciences 108:16, pages 6579-6584.
Crossref
Milena Soriano Marcolino, Antonio Luiz Ribeiro, Nelma C.D. Clementino, Maria do Carmo P. Nunes, Márcia M. Barbosa, Maria Helena C.R. Silva, Henrique N.S. Bittencourt, Marcel L. Geleijnse & Eric Boersma. (2011) The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leukemia Research 35:3, pages 317-322.
Crossref
Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi & Giuseppe Toglia. (2011) Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. Journal of Cardiovascular Echography 21:1, pages 32-41.
Crossref
Andrés F. Buitrago, Luis E. Silva, Leidy P. Prada & Libardo Lobato. (2011) Derrame pericárdico con inminente taponamiento cardiaco secundario a inhibidor de la tirosina quinasa. Reporte de un caso. Revista Colombiana de Cardiología 18:2, pages 119-123.
Crossref
Thomas Force & Kyle L. Kolaja. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Reviews Drug Discovery 10:2, pages 111-126.
Crossref

Displaying 200 of 216 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.